mitochondrial DNA
Aditxt Subsidiary Pearsanta Acquires MDNA Life Sciences Cancer Testing Platform for Over $25M
In the deal, Pearsanta gained the Mitomic Endometriosis and Prostate Cancer tests, as well as a development pipeline of other cancer assays.
Mitochondrial DNA Damage May Serve as Biomarker of Parkinson's Disease
Researchers at Duke University detected mitochondrial DNA damage in Parkinson's patients with and without mutations in LRRK2, a well-known cause of the disease.
MDNA Life Sciences Signs Southeast Asian Distribution Deal for Prostate Cancer Test
The PCR-based test analyzes mitochondrial DNA to detect prostate cancer in advance of biopsy, independent of prostate-specific antigen levels and age.
LabCorp Licensing MDNA Liquid Biopsy-Based Prostate Cancer Technology
LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
The company has rededicated itself to a fully blood-based test pipeline, with its next assays focused on women's health, including endometriosis and ovarian, uterine, and cervical cancers.